Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in CombinationPierre Mordant, Éric Deutsch|Molecular Cancer Therapeutics|2010Cited by 48